TD Cowen Increases Abbott Laboratories (NYSE:ABT) Price Target to $135.00

Abbott Laboratories (NYSE:ABT) had its target price boosted by analysts at TD Cowen from $115.00 to $135.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the healthcare product maker’s stock. TD Cowen’s price target would indicate a potential upside of 16.26% from the company’s previous close.

Several other research firms have also issued reports on ABT. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Wells Fargo & Company boosted their target price on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and set a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, Citigroup lifted their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Trading Down 0.5%

NYSE:ABT traded down $0.55 during trading hours on Tuesday, hitting $116.12. 7,502,958 shares of the company were exchanged, compared to its average volume of 11,820,817. The company has a fifty day simple moving average of $100.64 and a 200 day simple moving average of $100.03. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The stock has a market capitalization of $200.94 billion, a price-to-earnings ratio of 37.58, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The business’s quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

Institutional investors have recently modified their holdings of the company. Nia Impact Advisors LLC grew its position in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after purchasing an additional 79 shares during the period. Riggs Asset Managment Co. Inc. lifted its stake in shares of Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 88 shares in the last quarter. Eley Financial Management Inc grew its holdings in shares of Abbott Laboratories by 0.9% during the fourth quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after buying an additional 92 shares during the last quarter. Copley Financial Group Inc. increased its position in shares of Abbott Laboratories by 2.1% during the fourth quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after acquiring an additional 93 shares in the last quarter. Finally, Kelleher Financial Advisors increased its position in shares of Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after acquiring an additional 93 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first wearable device designed to continuously monitor both glucose and ketone levels. The system may help detect rising ketones associated with diabetic ketoacidosis, expands Abbott’s FreeStyle Libre ecosystem and is designed to work with automated insulin-delivery systems. The approval strengthens Abbott’s competitive position in the continuous glucose-monitoring market and could create a new growth opportunity. FDA authorizes Abbott’s wearable to monitor ketone and glucose in diabetes patients
• Positive Sentiment: Analyst comparisons with DexCom characterize Abbott as having more attractive valuation and price-target upside, while both companies pursue growth through CGM adoption and product innovation. Abbott also benefits from the launch of Medtronic’s MiniMed Flex pump using an Abbott-made sensor, which could support sensor demand and broaden ecosystem exposure. Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?
• Neutral Sentiment: Abbott’s diagnostics business shows healthy routine testing demand and 13% growth in cancer diagnostics, but weaker respiratory testing is offsetting part of that momentum. This creates a mixed near-term outlook for the segment. Here’s What Is Shaping Abbott’s Diagnostics Growth
• Neutral Sentiment: Recent institutional activity was mixed: Golden Reserve Retirement LLC increased its Abbott position substantially, while Choreo LLC reduced its holdings modestly. These changes are relatively small and unlikely to materially affect the stock.
• Negative Sentiment: Abbott agreed to pay approximately $670 million to settle claims involving about 2,000 premature infants whose families alleged its specialized formulas contributed to necrotizing enterocolitis. Although the settlement removes uncertainty surrounding a major verdict and does not admit liability, it highlights continuing litigation exposure and imposes a significant financial charge. Abbott Pays $670 Million to Settle Formula Claims as Legal Risks Persist

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.